{"Symbol": "ALEC", "AssetType": "Common Stock", "Name": "Alector Inc", "Description": "Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.", "CIK": "1653087", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "131 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080", "OfficialSite": "https://www.alector.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "204113000", "EBITDA": "-115693000", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.537", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.06", "RevenuePerShareTTM": "0.689", "ProfitMargin": "-1.56", "OperatingMarginTTM": "-11.54", "ReturnOnAssetsTTM": "-0.178", "ReturnOnEquityTTM": "-1.22", "RevenueTTM": "69048000", "GrossProfitTTM": "-116892000", "DilutedEPSTTM": "-1.06", "QuarterlyEarningsGrowthYOY": "-0.863", "QuarterlyRevenueGrowthYOY": "-0.788", "AnalystTargetPrice": "2.1", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "1", "AnalystRatingHold": "5", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "1", "TrailingPE": "-", "ForwardPE": "8.47", "PriceToSalesRatioTTM": "2.956", "PriceToBookRatio": "3.546", "EVToRevenue": "0.641", "EVToEBITDA": "-8.4", "Beta": "0.631", "52WeekHigh": "3.4", "52WeekLow": "0.87", "50DayMovingAverage": "1.671", "200DayMovingAverage": "1.835", "SharesOutstanding": "109151000", "SharesFloat": "78194000", "PercentInsiders": "10.122", "PercentInstitutions": "86.193", "DividendDate": "None", "ExDividendDate": "None"}